- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Medical Information
- Phone Number: 844-454-5483(1-844-454-KITE)
- Email: medinfo@kitepharma.com
Study Locations
-
-
-
Wuerzburg, Germany, 97080
- Recruiting
- Universitätsklinikum Würzburg
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Recruiting
- Academisch Medisch Centrum
-
-
-
-
-
London, United Kingdom, SE5 9RS
- Recruiting
- King's College Hospital
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner MD Anderson Cancer Center
-
-
California
-
Stanford, California, United States, 94305
- Recruiting
- Stanford Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of MD, Greenebaum Comprehensive Cancer Center
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas, MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Relapsed and/or refractory B-cell lymphoma (R/R BCL).
- At least 1 measurable lesion.
- Adequate organ and bone marrow (BM) function.
Key Exclusion Criteria:
- History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease free and without anticancer therapy (with the exception of hormonal therapy in the case of breast cancer) for at least 3 years.
- History of Richter's transformation of chronic leukemic lymphoma, small lymphocytic lymphoma, or lymphoplasmacytic lymphoma.
- History of allogeneic stem cell transplant (allo-SCT).
- Auto-SCT within 6 weeks before the planned KITE-363 or KITE-753 infusion.
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requires intravenous (IV) antimicrobials for management.
- Known history of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) hepatitis B surface (HBs) antigen (HBsAg) positive infection, or hepatitis C (anti-hepatitis C virus [HCV] positive) infection.
- Individuals with detectable cerebrospinal fluid (CSF) malignant cells or brain metastases or a history of central nervous system (CNS) lymphoma, primary CNS lymphoma, or spinal epidural involvement.
- History or presence of a CNS disorder.
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, active arrhythmia, New York Heart Association Class II or greater congestive heart failure or other clinically significant cardiac disease within the 6 months before enrollment.
- Primary immunodeficiency.
- History of autoimmune disease resulting in or requiring systemic immunosuppression and/or systemic disease-modifying agents within the last 2 years.
- History of non-line associated, clinically significant deep-vein thrombosis or pulmonary embolism requiring therapeutic anticoagulation within the 6 months before enrollment.
- Females of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or have been postmenopausal for at least 2 years are not considered to be of childbearing potential.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KITE-363
Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363. Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable. |
Lymphodepleting chemotherapy administered intravenously
Lymphodepleting chemotherapy administered intravenously
A single infusion of CAR-transduced autologous T cells administered intravenously
|
Experimental: KITE-753
Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753. Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable. |
Lymphodepleting chemotherapy administered intravenously
Lymphodepleting chemotherapy administered intravenously
A single infusion of CAR-transduced autologous T cells administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753
Time Frame: Up to 28 days
|
DLTs are defined as the KITE-363-related or KITE-753-related events with onset within the first 28 days after the infusion of KITE-363 or KITE-753 respectively.
|
Up to 28 days
|
Phase 1b: Objective Response Rate (ORR) for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
ORR is defined as the percentage of participants with a complete response (CR) or a partial response (PR) by the International Working Group (IWG) Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) as determined by investigator assessment.
|
Up to 15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Serum Levels of Key Analytes Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Peak Serum Levels of Key Analytes Inflammatory/Immune Modulating Cytokines: IFN-γ, IL-6, IL-10, IL-17, IL-1RA, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), and Tumor Necrosis Factor-Alpha (TNF-α)
Time Frame: Up to 3 months
|
IFN-γ=Interferon-Gamma, IL-1 Receptor Antagonist=IL-1RA
|
Up to 3 months
|
Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: C-Reactive Protein (CRP)
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Ferritin
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Soluble IL-2 Receptor Alpha (Sil-2Rα)
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Peak Serum Levels of Key Analytes Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Peak Serum Levels of Key Analytes Immune-Effector Molecules: Perforin, Granzyme A, and Granzyme B
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Percentage of Participants Experiencing Adverse Events (AEs) After the Infusion of KITE-363 or KITE-753
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Percentage of Participants Experiencing Serious AEs (SAEs) After the Infusion of KITE-363 or KITE-753
Time Frame: Up to 15 years
|
Up to 15 years
|
|
Time To Next Treatment (TTNT) for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
TTNT is defined as the time from KITE-363 or KITE-753 infusion to the next anticancer treatment (including stem cell transplantation [SCT]) or death from any cause, whichever occurs first.
|
Up to 15 years
|
Complete Response (CR) Rate for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
CR rate is defined as the incidence of a CR by the IWG Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) as determined by investigator assessment.
|
Up to 15 years
|
Duration of Response (DOR) for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression per the IWG Lugano Classification or death due to any cause, whichever occurs first.
|
Up to 15 years
|
Progression-Free Survival (PFS) for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
PFS is defined as the time of KITE-363 or KITE-753 infusion to disease progression per IWG Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) or death from any cause, whichever occurs first.
|
Up to 15 years
|
Overall Survival (OS) for KITE-363 or KITE-753
Time Frame: Up to 15 years
|
OS is defined as the time from KITE-363 or KITE-753 infusion to death from any cause.
|
Up to 15 years
|
Percentage of Participants who Develop Antibodies to KITE-363 or KITE-753 Chimeric Antigen Receptor (CAR) T Cells
Time Frame: Enrollment; up to 12 months
|
Enrollment; up to 12 months
|
|
Levels of KITE-363 or KITE-753 CAR T Cells and Analytes (Including Cytokines) in the Blood
Time Frame: Up to 15 years
|
Up to 15 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kite Study Director, Kite, A Gilead Company
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- KT-US-499-0150
- 2020-000562-41 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and/or Refractory B-cell Lymphoma
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
-
Allogene TherapeuticsRecruitingRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaUnited States, Spain, Canada, Australia, Italy
-
University Health Network, TorontoTakara Bio Inc.RecruitingRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell LymphomaCanada
-
AstraZenecaActive, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaChina
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health HospitalRecruitingRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin LymphomaChina
-
Prelude TherapeuticsCompletedAdenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...United States
-
Miltenyi Biomedicine GmbHActive, not recruitingNon-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma RecurrentGermany
-
BeiGeneRecruitingRefractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditionsChina, Australia
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted